Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy

H Hua, Q Kong, J Yin, J Zhang, Y Jiang - Journal of hematology & …, 2020 - Springer
growth factor (HGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF),
and insulin-like growth factor … and invasion thereby promoting tumor growth, angiogenesis, …

[HTML][HTML] Tumor angiogenesis: Current challenges and therapeutic opportunities

FH Al-Ostoot, S Salah, HA Khamees… - Cancer Treatment and …, 2021 - Elsevier
… of oxygen, nutrients, and growth factors as well as tumor dissemination to distant organs. …
solid tumors that depend on cutting or at least reducing the blood supply to tumor micro-…

CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target

L Li, L Zhong, C Tang, L Gan, T Mo, J Na, J He… - Clinical and …, 2022 - Springer
therapies [5]. Anti-angiogenic therapies targeting the vascular endothelial growth factor (…
angiogenesis therapy [7] and tumor prevention based on its expression in blood vessels [8]. …

The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications

R Tamura, T Tanaka, Y Akasaki, Y Murayama… - Medical Oncology, 2020 - Springer
… Vascular endothelial growth factor (VEGF) is a key mediator of tumor angiogenesis … factor
and its receptor [29]. TAMs induce various growth factors such as basic fibroblast growth factor, …

Transforming growth factor-β signaling in fibrotic diseases and cancer-associated fibroblasts

X Shi, CD Young, H Zhou, XJ Wang - Biomolecules, 2020 - mdpi.com
… Higher self-renewal ability (stemness) of CSCs, which means more CSCs in the tumor,
indicates a higher possibility of anti-tumor therapy resistance. CAF-secreted TGF-β2 activated …

[HTML][HTML] Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

E Martinelli, D Ciardiello, G Martini, T Troiani… - Annals of …, 2020 - Elsevier
… be associated with increased levels of vascular endothelial growth factor and that inhibiting
angiogenesis could contribute to tumor growth inhibition. Under the selective pressure of …

Angiogenic signaling pathways and anti-angiogenic therapy for cancer

ZL Liu, HH Chen, LL Zheng, LP Sun… - … and targeted therapy, 2023 - nature.com
… maintain the tumor growth. A … tumor tissue, which releases abundant growth factors and
cytokines, stimulating angiogenesis and lymphangiogenesis to meet the needs of tumor growth

Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target

PS Filippou, GS Karagiannis, A Constantinidou - Oncogene, 2020 - nature.com
… the majority of tumor cells in human malignant tumors [9, 22] and this will be the highlighted
topic of the current review. As mentioned, MDK functions as a cytokine and growth factor with …

YAP/TAZ: drivers of tumor growth, metastasis, and resistance to therapy

BJ Thompson - Bioessays, 2020 - Wiley Online Library
… and tumor suppressors that primarily affect a handful of signal transduction pathways, most
importantly the growth factor … targeted therapeutics against growth factor signaling have had …

Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity

J Lai, S Mardiana, IG House, K Sek… - Nature …, 2020 - nature.com
… CAR T cells in solid tumors. Given that Flt3L is a critical growth factor for DCs 6 , we hypothesized
that armored T cells engineered to secrete Flt3L can overcome tumor heterogeneity by …